This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| TGFB1 | |
|---|---|
| Name | Transforming growth factor beta-1 |
| Caption | Crystal structure of latent TGF-β1 |
| Uniprot | P01137 |
| Gene | TGFB1 |
| Organism | Homo sapiens |
| Length | 390 aa precursor |
TGFB1 TGFB1 encodes transforming growth factor beta-1, a secreted cytokine central to World Health Organization-scale immunoregulatory processes and studied across institutions such as National Institutes of Health and The Rockefeller University. Discovered in tumor biology research at Cold Spring Harbor Laboratory and characterized in studies involving Roswell Park Comprehensive Cancer Center and Max Planck Society collaborators, TGFB1 links developmental biology research from University of Cambridge to translational programs at Memorial Sloan Kettering Cancer Center. Its roles intersect investigations by Nobel Prize-winning pathways and by consortia including Human Genome Project participants.
TGFB1 is encoded on human chromosome 19 and produces a 390-amino-acid precursor processed to a 112-amino-acid mature peptide; gene mapping involved projects at National Human Genome Research Institute and sequencing efforts by Sanger Centre. The precursor comprises a signal peptide, a latency-associated peptide (LAP), and the mature growth factor domain; structural elucidation utilized techniques from European Molecular Biology Laboratory, Harvard Medical School, and Stanford University crystallography facilities. The mature domain forms a disulfide-linked dimer whose three-dimensional fold was resolved through collaborations with laboratories at CNRS and the Max Planck Institute for Biophysical Chemistry. Genetic variation studies linking TGFB1 polymorphisms to phenotypes were conducted in cohorts from Framingham Heart Study, UK Biobank, and Nurses' Health Study.
TGFB1 transcription and secretion are regulated by stimuli characterized in models from Johns Hopkins University and UCLA, including transforming influences such as platelet activation studied at Mayo Clinic and inflammatory signaling profiled by teams at Karolinska Institutet. Promoter elements respond to transcription factors identified in Cold Spring Harbor and University of California, San Francisco research, including regulators noted in publications from Cell Press and Nature Publishing Group. Post-translational control involves cleavage by proteases investigated at Rockefeller University and association with latent TGF-β binding proteins described in studies at Weizmann Institute of Science and ETH Zurich. Secretion and activation were delineated using models from Massachusetts General Hospital and Imperial College London.
TGFB1 signals principally through serine/threonine kinase receptors, type I and II, whose intracellular transducers include SMAD family proteins characterized in seminal work at University of California, Berkeley and Cold Spring Harbor Laboratory. Canonical SMAD2/3-SMAD4 complexes translocate to the nucleus to regulate transcription; non-canonical pathways involving MAPK, PI3K-AKT and Rho GTPases were defined in laboratories at MIT and University of Oxford. Crosstalk with pathways implicated in cancer research at Dana-Farber Cancer Institute and developmental signaling studied at The Salk Institute integrate inputs from receptor endocytosis elucidated in studies at Yale University and University of Pennsylvania.
TGFB1 modulates immune responses investigated at Emory University and Baylor College of Medicine, where its role in regulatory T cell biology and macrophage polarization was mapped. It controls extracellular matrix production and fibroblast activity, central to fibrosis studies at Cleveland Clinic and Johns Hopkins Hospital. TGFB1 influences epithelial-mesenchymal transitions characterized in cancer centers including Memorial Sloan Kettering Cancer Center and University College London, and impacts angiogenesis researched at Max Planck Society and The Francis Crick Institute.
Developmental roles of TGFB1 were explored in vertebrate models at California Institute of Technology and University of Chicago, where effects on organogenesis, limb formation, and neural crest derivatives were reported. In tissue homeostasis, TGFB1 maintains stem cell niches studied at Broad Institute and Stanford Medicine, regulates wound healing protocols examined at Rush University Medical Center and contributes to immune tolerance mechanisms investigated in transplant programs at Cleveland Clinic and Mayo Clinic.
Aberrant TGFB1 signaling is implicated in cancer progression, metastasis, and immune evasion described in reports from Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, and Fred Hutchinson Cancer Center. Elevated TGFB1 activity underlies fibrotic diseases examined at National Jewish Health and University of Pittsburgh Medical Center, including pulmonary fibrosis and liver cirrhosis analyzed by consortia with European Respiratory Society and American Association for the Study of Liver Diseases. Contributions to cardiovascular remodeling were reported in cohorts from Framingham Heart Study and studies at Mount Sinai Hospital. Genetic association studies linking TGFB1 variants to susceptibility were conducted by teams at Wellcome Trust and deCODE genetics.
TGFB1-directed therapies are pursued across academic-industry collaborations involving Genentech, Pfizer, and Novartis, with strategies including receptor kinase inhibitors, neutralizing antibodies, and ligand traps tested in trials coordinated by Food and Drug Administration-registered centers and oncology networks such as SWOG. Antifibrotic programs incorporating TGFB1 antagonists were advanced at Bayer and evaluated in multicenter trials with participation from European Medicines Agency-reported sites. Challenges include context-dependent tumor-suppressive versus tumor-promoting effects outlined by investigators at Dana-Farber Cancer Institute and regulatory considerations addressed in guidance from World Health Organization and European Commission agencies.
Category:Human proteins